推荐活动

专注生物医药求职招聘
P4 China 2017 第二届国际精准医疗大会

重磅!牛津肿瘤生物标志物公司宣布同宁波梅傲生物科技有限公司进行战略合作

首页 » 产业 » 企业 2017-04-24 转化医学网 赞(4)
分享: 
导读
合作将促进牛津肿瘤生物标志物公司(OCB)的精准肿瘤体外检测技术全面进入中国市场

总部位于英国的牛津肿瘤生物标志物公司是一家致力于让癌症患者能够从个性化治疗中获益的检测产品研发公司。20173月,宣布同中国宁波梅傲生物科技有限公司开始战略合作。

合作内容包括梅傲生物公司将获得OCB的三项技术许可,ColoTox (畅乐妥,氟尿嘧啶药物毒性预测), ColoProg (畅乐复,结直肠癌患者术后复发风险预测), ColoPredict (畅乐普,结直肠癌遗传性患病风险预测).将通过在建中的宁波梅山保税港区医学检验所推动在中国市场的业务。

OCB针对目前个性化的治疗途径,已经开发了一系列结直肠癌的检测产品,并计划开发其他癌症类似的检测产品。2015年,在中国每年有374,000人被诊断患有结直肠癌,其中每年有190,400例死于结直肠癌。

梅傲生物是一家领先的精准医疗商业化机构,致力于将全球的创新发明引入中国市场。梅傲的团队拥有丰富的产品开发和上市经验,包括临床研究、注册策略、临床实验室服务和营销。梅傲生物的核心商业模式是以病人和临床的需求驱动。

朱炜焰,梅傲生物首席执行官评论说:“很高兴能上市由牛津大学发明,OCB公司开发的三项专利结直肠癌检测产品,中国病人会从获得实实在在的益处。梅傲和OCB有坚实的伙伴关系,将通过开发和上市系列独特的后续精准诊断产品来体现对对中国市场的长期承诺”。

OCB的首席医学官,David Kerr教授评论说:“我们同梅傲的战略伙伴关系将使中国病人能够获得OCB的系列肿瘤精准诊断技术。我们期望同梅傲密切合作,为中国市场的特殊需求量身定制我们的产品和服务,并建设一个更强有力的针对中国人群的精准诊断产品线。这为实现我们的使命迈出了一大步–“推动全球患者通过获得我们的技术来实现分级和个体化的定制诊疗路径”。

- Ends -

关于牛津肿瘤生物标志物公司:

牛津肿瘤生物标志物公司将开创性的科学发现转变为预测性的生物标志物检测产品,这些个性化治疗的检测产品可以使癌症患者受益。牛津肿瘤生物标志物公司是牛津大学旗下衍生公司,其与牛津大学医学研究院有着密切的联系。牛津肿瘤生物标志物公司是由牛津大学癌症生物学主席Nick La Thangue博士和牛津大学癌症医学教授DavidKerr爵士创立的。牛津肿瘤生物标志物公司的投资方包括Longwall风险投资有限合伙公司,EsperanteBV和牛津大学。

详细联系方式

Oxford Cancer Biomarkers Ltd                  Tel:  +44 1865 784743

牛津肿瘤生物标志物有限公司

Prof. Nick La Thangue, CEO / David Oxlade, Chairman

关于宁波梅傲生物科技有限公司

基于“连接世界的精准医疗创新平台”之愿景,梅傲生物将致力于:为临床和患者提供个体化的临床垂直解决方案,并建立一体化的创新技术商业化平台。成立于20165月的梅傲生物,依托宁波梅山生命健康发展大战略,聚集了一批产业化平台所需的优质人才,具备全球业务拓展、市场准入、临床研究、注册、医学检测服务、营销等方面的能力。其全资子公司宁波梅山保税港区梅傲医学检验所已通过获得卫计委前置审批,年内获得医学检验所资质。

详细联系方式

Ningbo My-BioMed Biotechnology Co.,Ltd.     E-Mailinfo@my-biomed.com

宁波梅傲生物科技有限公司

CEO:朱炜焰 Jackson Zhu


Oxford Cancer Biomarkers announces strategic collaboration with My-BioMed Biotechnology Co. Ltd

Collaboration will allow OCB’s suite of precision oncology In Vitro Diagnostic tests to be rolled out across the People’s Republic of China

Oxford, UK, April 2017 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced a strategic collaboration with My-BioMed Biotechnology Co. Ltd. based in Ningbo, Zhejiang, China.

The partnership includes a licencing deal that will allow My-BioMed Biotechnology Ltd to access OCB’s ColoTox, ColoProg and ColoPredict technologies and to drive uptake across the People’s Republic of China via a purpose built biomedical laboratory in Ningbo Meishan FTZ.

OCB has developed a suite of diagnostic tests for colorectal cancer (CRC) to personalise current treatment pathways and plans to develop similar tests for other cancer indications. As of 2015, 274,000 new cases of colorectal cancer are diagnosed every year in the Peoples Republic of China, 190,400 of these cases prove fatal.

My-BioMed (MBM) is a leading precision medicine organisation, focussed on bringing global innovation to the Chinese market. The team at MBM has extensive experience in product development and launch including clinical development, regulatory strategy, clinical laboratory services, sales and marketing. MBM’s core business model is driven by patient and clinician needs.

Jackson Zhu, CEO of MBM, commented “We are very happy to launch the first three proprietary CRC diagnostic tests discovered at Oxford University and developed by OCB, aimed at specifically benefitting patients in China. Through this partnership MBM and OCB have solidified a long term commitment to China, with the aim of developing and launching a suite of unique diagnostic products.”

Prof David Kerr, Chief Medical Officer of OCB, commented “Our strategic partnership with MBM will allow patients across China to access OCB’s suite of precision oncology diagnostic technologies. We are looking forward to working closely with MBM to tailor our offerings to the specific needs of the Chinese market and building a robust product pipeline of diagnostics specifically aimed at the Chinese population. This is an important step in our mission to drive global access to technologies that allow patient stratification and individually tailored treatment pathways.”

About Oxford Cancer Biomarkers

Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division in Oxford University. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University. Investors in OCB include Longwall Venture Partners LLP, Esperante BV and the University.

For more information, please visit: http://www.oxfordcancerbiomarkers.com

Contact details

Oxford Cancer Biomarkers Ltd

Tel: +44 1865 784743

Nick La Thangue, CEO / David Oxlade, Chairman

About Ningbo My-BioMed Biotechnology Co.,Ltd.

In pursuit of its vision of “Bridging World Innovation in Precision Medicine”, My-BioMed (MBM) is dedicated to providing personalized solutions to clinicians and patients, and to building an integrated commercialization platform for innovation.

Supported by Ningbo Meishan’s Healthcare industry development strategy, MBM, established in May 2016, has attracted a group of talented individuals with experience across a range of disciplines including; business development, market access, clinical development, registration, clinical lab services, sales and marketing. Located at Ningbo Meishan Free Trade Port, My-BioMed Clinical Laboratory, MBM wholly owned subsidiary, has been granted pre-approval from the Health and Family Plan Commission, and will be certified within this year.

Contact details

Ningbo My-BioMed Biotechnology Co., Ltd.

E-Mailinfo@my-biomed.com

Jackson Zhu, CEO


(转化医学网360zhyx.com)

评论:
评 论
共有 0 条评论

    还没有人评论,赶快抢个沙发